Tillkännagivande • Apr 01
FOXO Technologies Inc. announced delayed annual 10-K filing On 03/31/2026, FOXO Technologies Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Tillkännagivande • Dec 16
FOXO Technologies Inc. Provides Revenue Guidance for the Year Ended December 31, 2025 FOXO Technologies Inc. provided revenue guidance for the year ended December 31, 2025. The company expected to exceed $15 million in net revenues for the full year ended December 31, 2025. Tillkännagivande • Sep 27
Foxo Technologies Inc. Appoints Sylwia Nowak Hauman as Chief Financial Officer On September 23, 2025, FOXO Technologies Inc. appointed Sylwia Nowak Hauman (age 50) as the Company’s Chief Financial Officer (Principal Financial and Accounting Officer). Ms. Hauman has more than 25 years of finance and administrative leadership expertise in public and private multi-billion and start-up companies including extensive pharmaceutical and biotech experience from several multinational companies including Pearsanta, Aditxt (VP, Corporate Controller from May 2022 to September 2024), Lonza, Air Liquide Advanced Materials (Controller from September 2018 to August 2020), Johnson & Johnson, Accord Healthcare (Finance Director – Sales & Gross to Net from January 2020 to April 2022), and Alvogen as well as FDA regulated companies such as, Unilever and Avon. She has served as VP of Finance at Payall Payment Systems Inc. from September 2024 to the present. She has run and managed several international projects and helped design the Innovation Process Management method to successfully develop and commercialize new technologies. Ms. Hauman is a Certified Accountant, holds a Master’s degree in finance and Banking from Lodz University and is qualified in both US GAAP and IFRS. Tillkännagivande • Sep 23
FOXO Technologies Inc. (NYSEAM:FOXO) acquired Vector Biosource Inc. FOXO Technologies Inc. (NYSEAM:FOXO) signed a non-binding agreement to acquire Vector Biosource Inc. on March 19, 2025. FOXO Technologies Inc. (OTC: FOXO) signed a stock purchase agreement to acquire Vector Biosource Inc. on September 9, 2025. The expected purchase price consists of: (i) $0.5 million in cash, (ii) 0.06 million shares of the FOXO Technologies Inc.’s Series E Cumulative Redeemable Secured Preferred Stock (the “Series E Preferred Stock”) ($1.5 million in stated value), (iii) warrants to purchase $2 million of the FOXO Technologies Inc.’s common stock at a 10% premium to the common stock’s closing price one day prior to closing, and (iv) up to an additional 80,000 shares of Series E Preferred Stock (up to $2.0 million in stated value) subject to achieving certain revenue and cash collection milestones in a future 12 to 24 month period. Closing is expected to occur as soon as practical after a number of closing conditions are satisfied including, but not limited to, completion of due diligence and forms of warrant and employment agreements being finalized. In addition, FOXO Technologies Inc. has agreed to fund up to $1.2 million of Vector BioSource’s growth initiatives. The purchase price includes $0.75 million in Series D Preferred Stock at closing, an additional $0.75 million in Series D Preferred Stock contingent on 2025 revenue and cash collection milestones, and earnout payments in Series D Preferred Stock based on 2026-2027 performance. The transaction is subject to definitive agreements (expected within 45 days), satisfactory due diligence, $1 million in working capital, and other closing conditions. Closing is expected to occur as soon as practical after a number of closing conditions are satisfied including, but not limited to, completion of due diligence and forms of warrant and employment agreements being finalized. In addition, FOXO Technologies Inc. has agreed to fund up to $1.2 million of Vector BioSource’s growth initiatives.
FOXO Technologies Inc. (NYSEAM:FOXO) acquired Vector Biosource Inc. on September 22, 2025. Tillkännagivande • Aug 15
FOXO Technologies Inc. announced delayed 10-Q filing On 08/14/2025, FOXO Technologies Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Tillkännagivande • Aug 08
FOXO Technologies Inc. (NYSEAM:FOXO) signed a non-binding acquisition agreement to acquire An assisted living and memory care facility in South Florida for $22 million. FOXO Technologies Inc. (NYSEAM:FOXO) signed a non-binding acquisition agreement to acquire An assisted living and memory care facility in South Florida for $22 million on August 7, 2025. The purchase price for the facility is expected to be $22 million, a portion of which is milestone-based. $5 million of the purchase price will be in the form of non-convertible preferred stock. Furthermore, the Company expects to shortly confirm a definitive agreement that is at an advanced stage of completion for the acquisition of Vector Biosource, Inc., that was previously announced. The Company continues to explore and negotiate additional opportunities in the assisted living and behavioral health sector and is confident that the expansion of its Myrtle Recovery Centers, Inc. business is imminent. Completion of the acquisition is subject to definitive agreements and a number of closing conditions, including satisfactory due diligence and financing. Tillkännagivande • Jun 20
FOXO Technologies Inc. announced that it has received $1.65 million in funding On June 20, 2025, FOXO Technologies Inc closed the transaction. Tillkännagivande • Jun 16
FOXO Technologies Inc Announces Interim Chief Financial Officer Changes On June 13, 2025, the Board of Directors of the FOXO Technologies Inc. appointed Seamus Lagan to serve as the Company’s Interim Chief Financial Officer. On June 9, 2025, Martin Ward, the Company’s Interim Chief Financial Officer passed away unexpectedly. Mr. Lagan will be the Company’s principal financial officer and principal accounting officer on an interim basis and the Company will initiate a search for a new Chief Financial Officer. Seamus Lagan, age 56, has served as a director of the Company since September 10, 2024 and has served as the Company’s Chief Executive Officer since December 5, 2024. Mr. Lagan was appointed Chief Executive Officer and President and a director of Rennova Health Inc. (“RHI”), a company subject to section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), on November 2, 2015 and as Chief Executive Officer and a director of Medytox Solutions Inc., the predecessor business to a merger with RHI in 2015, and now a wholly-owned subsidiary of RHI (“Medytox”), effective September 15, 2014. Mr. Lagan served as Interim Chief Financial Officer of RHI from September 30, 2016 through May 24, 2017. He was again appointed Interim Chief Financial Officer effective October 13, 2017, and served through April 8, 2019. Mr. Lagan has also been the Interim Chief Financial Officer of RHI since May 10, 2019. Mr. Lagan has been, through Alcimede LLC until November 1, 2021 and Alcimede Limited since November 1, 2021, a consultant to Medytox since May 2011. Mr. Lagan is the managing director of Alcimede Limited, a Bahamas company that provides various consulting services, including management, organization, and financial consulting services. Mr. Lagan also currently serves, through Alcimede Limited, as chief executive officer of most of the subsidiaries of RHI and is the Chief Executive officer of the Company’s subsidiary Rennova Community Health Inc. Tillkännagivande • May 23
FOXO Technologies Inc. announced that it has received $0.55 million in funding On May 22, 2025 FOXO Technologies Inc. closed the transaction and received gross proceeds of $550,000. The transaction includes participation from a single investor. Tillkännagivande • May 16
FOXO Technologies Inc. announced delayed 10-Q filing On 05/15/2025, FOXO Technologies Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Tillkännagivande • Apr 22
FOXO Technologies Inc. announced that it has received $0.325 million in funding On April 21, 2025 FOXO Technologies Inc. closed the transaction and raised $325,000 in funding. The transaction includes participation from a single investor. Tillkännagivande • Apr 01
FOXO Technologies Inc. announced delayed annual 10-K filing On 03/31/2025, FOXO Technologies Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Board Change • Feb 14
Less than half of directors are independent There are 4 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 4 new directors. 3 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Chairman of the Board & Member of Scientific Advisory Board Bret Barnes is the most experienced director on the board, commencing their role in 2021. Independent Director Francis deWolf was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors. Tillkännagivande • Dec 24
FOXO Technologies Inc., Annual General Meeting, Dec 31, 2024 FOXO Technologies Inc., Annual General Meeting, Dec 31, 2024. Tillkännagivande • Dec 11
Foxo Technologies Inc. Appoints Seamus Lagan as Chief Executive Officer FOXO Technologies Inc. announced that Seamus Lagan has been appointed Chief Executive Officer of the Company effectively immediately. Mr. Lagan joined the Board of Directors of the Company on September 10, 2024. Seamus Lagan, age 55, has served as a director of the Company since September 10, 2024 and was appointed Chief Executive Officer and President and a director of Rennova Health Inc., in 2015, and is the Chief Executive Officer of the Company’s subsidiary, Rennova Community Health Inc. He has been an entrepreneur and investor in startup and distressed companies for over 30 years and has held numerous board and executive positions in publicly-listed companies. He has secured in excess of $100 million in funding for various projects and companies and has significant experience in mergers and acquisitions in the health care sector. Tillkännagivande • Dec 05
FOXO Technologies Inc. announced that it has received $0.22 million in funding On December 4, 2024, FOXO Technologies Inc. closed the transaction. The transaction included participation from 2 investors. Tillkännagivande • Nov 15
FOXO Technologies Inc. announced delayed 10-Q filing On 11/14/2024, FOXO Technologies Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Board Change • Nov 14
Less than half of directors are independent There are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. 3 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). Independent Chairman of the Board & Member of Scientific Advisory Board Bret Barnes is the most experienced director on the board, commencing their role in 2021. They were also the last independent director to join the board. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors. Tillkännagivande • Oct 29
FOXO Technologies Inc. announced that it has received $0.297033 million in funding from Kr8 ai Inc. On October 29, 2024 FOXO Technologies Inc. closed the transaction and received $40,533 in its final tranche. Tillkännagivande • Oct 28
FOXO Technologies Inc. announced that it has received $0.2565 million in funding On October 28, 2024, FOXO Technologies Inc. closed the transaction. The transaction included participation from a single investor. Tillkännagivande • Sep 18
FOXO Technologies Inc. (NYSEAM:FOXO) completed the acquisition of Rennova Community Health, Inc. from Rennova Health, Inc.(OTCPK:RNVA) for $20 million. FOXO Technologies Inc. (NYSEAM:FOXO) agreed to acquire Rennova Community Health, Inc. from Rennova Health, Inc.(OTCPK:RNVA) for $20 million on June 10, 2024. The consideration consists of 0.02 million Class A Cumulative Convertible Redeemable Preferred Stock of FOXO to be issued. For the period ended December 31, 2023, RCHI reported net income of $18.7 million. The transaction is subject to subject to shareholder approval. Brian Higley, Esq. of Business Legal Advisors, LLC acted as legal advisor to FOXO Technologies Inc. and J. Thomas Cookson of Shutts & Bowen LLP acted as legal advisor to Rennova Health, Inc.
FOXO Technologies Inc. (NYSEAM:FOXO) completed the acquisition of Rennova Community Health, Inc. from Rennova Health, Inc.(OTCPK:RNVA) on September 17, 2024. Tillkännagivande • Aug 15
FOXO Technologies Inc. announced delayed 10-Q filing On 08/14/2024, FOXO Technologies Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Tillkännagivande • Aug 09
FOXO Technologies Regains Compliance with NYSE American On June 10, 2024, FOXO Technologies Inc. received an official notice of noncompliance from NYSE Regulation (“NYSE”) stating that the Company is not in compliance with NYSE American continued listing standards due to an outstanding balance of listing fees over 180 days old and NYSE provided the Company until June 7, 2024 to provide payment before the Company would become subject to the noncompliance procedures. On August 7, 2024, the Company received a letter from NYSE stating that the Company is back in compliance with the NYSE American continued listed standards pertaining to timely payment of listing fees set in Section 1003(f)(iv) of the NYSE American Company Guide. The letter acknowledged that the Company has paid its outstanding balance of fees. Tillkännagivande • Jul 17
FOXO Technologies Announces Receipt of Notice of Non-Compliance with NYSE Continued Listing Requirements; Reaffirms Commitment to Regaining Compliance with NYSE American FOXO Technologies Inc. reports that it has received an official notice of noncompliance from NYSE Regulation stating that the Company is not in compliance with Section 1003(a)(ii) of the Company Guide since it reported stockholders’ deficit of ($14.9) million as of March 31, 2024, and losses from continuing operations and/or net losses in its three most recent fiscal years ended December 31, 2023. Mark White, Interim CEO of FOXO, said, “The delinquency was due to the previously disclosed short-term capital allocation strategies. While we regret the delay, we have been in contact with NYSE and look forward to presenting our compliance plan in light of recent developments, including our recently announced planned acquisitions, which we believe would generate meaningful cashflow for the combined companies. While there can be no assurances, we intend to regain compliance with the NYSE American continued listing standards in the near future.” The Company is now subject to the procedures and requirements set in Section 1009 of the Company Guide. The Company also remains subject to the conditions set in NYSE’s letters dated June 12, 2023 (Initial Equity Notification), August 29, 2023 (Plan Acceptance Letter) for stockholders’ equity noncompliance, and June 10, 2024 for past due listing fee noncompliance. If the Company is not in compliance with each respective compliance deadline or does not make progress consistent with each respective plan during such plan periods, NYSE will initiate delisting proceedings as appropriate. The Company may appeal a staff delisting determination in accordance with Section 1010 and Part 12 of the Company Guide. The Company was required to contact NYSE by July 16, 2024 to confirm receipt of the NYSE American Notice and discuss any new developments of which NYSE staff may be unaware. Board Change • Jul 01
Less than half of directors are independent There are 3 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 3 new directors. 2 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). Independent Chairman of the Board & Member of Scientific Advisory Board Bret Barnes is the most experienced director on the board, commencing their role in 2021. They were also the last independent director to join the board. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors. Tillkännagivande • Apr 26
FOXO Technologies Announces Receipt of Notice of Non-Compliance with NYSE Continued Listing Requirements On April 17, 2024, FOXO Technologies Inc. (the ‘Company’) received an official notice of noncompliance (the ‘NYSE American Notice’) from NYSE Regulation (‘NYSE’) stating that the Company is not in compliance with NYSE American continued listing standards (the ‘Filing Delinquency Notification’) due to the failure to timely file the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 (the ‘Delinquent Report’) by the filing due date of April 16, 2024 (the ‘Filing Delinquency’). ‘Due to significant changes and essential restructuring undertaken in 2023, which has continued in 2024, there has been a delay in filing our Form 10-K,’ explained Mark White, Interim Chief Executive Officer of Foxo Technologies. ‘Despite these challenges, we've continued to make considerable operational and financial progress. We are fully dedicated to meeting the NYSE American's continued listing requirements and have implemented measures to greatly improve our financial systems and ensure the highest levels of corporate governance. At the same time, we continue to advance a potentially transformative transaction that we believe would drive significant value for our shareholders. We look forward to providing further updates on this and other positive developments as soon as practical.’ The Company is now subject to the procedures and requirements set forth in Section 1007 of the NYSE American Company Guide. Within five days of the date of the Filing Delinquency Notification, the Company was required to (a) contact the NYSE to discuss the status of the Delinquent Report and (b) issue a press release disclosing the occurrence of the Filing Delinquency, the reason for the Filing Delinquency and, if known, the anticipated date such Filing Delinquency will be cured via the filing or refiling of the applicable report, as the case may be. The NYSE American Notice has no immediate effect on the listing or trading of the Company’s Class A common stock on NYSE American. During the six-month period from the date of the Filing Delinquency (the ‘Initial Cure Period’), the NYSE will monitor the Company and the status of the Delinquent Report and any subsequent delayed filings, including through contact with the Company, until the Filing Delinquency is cured. If the Company fails to cure the Filing Delinquency within the Initial Cure Period, the NYSE may, in the NYSE’s sole discretion, allow the Company’s securities to be traded for up to an additional six-month period (the ‘Additional Cure Period’) depending on the Company’s specific circumstances. If the NYSE determines that an Additional Cure Period is not appropriate, suspension and delisting procedures will commence in accordance with the procedures set out in Section 1010 of the NYSE American Company Guide. If the NYSE determines that an Additional Cure Period of up to six months is appropriate and the Company fails to file its Delinquent Report and any subsequent delayed filings by the end of that period, suspension and delisting procedures will generally commence. An issuer is not eligible to follow the procedures outlined in Section 1009 with respect to these criteria. Notwithstanding the foregoing, however, the NYSE may in its sole discretion decide (i) not to afford an issuer any Initial Cure Period or Additional Cure Period, as the case may be, at all or (ii) at any time during the Initial Cure Period or Additional Cure Period, to truncate the Initial Cure Period or Additional Cure Period, as the case may be, and immediately commence suspension and delisting procedures if the Company is subject to delisting pursuant to any other provision of the Company Guide, including if the NYSE believes, in the NYSE’s sole discretion, that continued listing and trading of an issuer's securities on the NYSE is inadvisable or unwarranted in accordance with Sections 1001-1006 hereof. The Company intends to regain compliance with the NYSE American continued listing standards. There can be no assurance that the Company will ultimately regain compliance with all applicable NYSE American listing standards. Tillkännagivande • Apr 02
FOXO Technologies Inc. announced delayed annual 10-K filing On 04/01/2024, FOXO Technologies Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Tillkännagivande • Mar 21
FOXO Technologies Inc. announced that it has received $0.1422 million in funding On March 20, 2024, FOXO Technologies Inc. closed the transaction. The transaction included participation from a single investor Tillkännagivande • Feb 15
FOXO Technologies Inc. (NYSEAM:FOXO) entered into a non-binding agreement to acquire M2i Global, Inc. (OTCPK:MTWO). FOXO Technologies Inc. (NYSEAM:FOXO) entered into a non-binding agreement to acquire M2i Global, Inc. (OTCPK:MTWO) on February 14, 2024. Board Change • Feb 15
Less than half of directors are independent There are 3 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 3 new directors. 2 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). Independent Chairman of the Board & Member of Scientific Advisory Board Bret Barnes is the most experienced director on the board, commencing their role in 2021. They were also the last independent director to join the board. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors. Tillkännagivande • Feb 13
FOXO Technologies Inc. announced that it has received $0.45747 million in funding On February 12, 2024, FOXO Technologies Inc. closed the transaction. The transaction included participation from a single investor. Tillkännagivande • Dec 19
FOXO Technologies Announces Receipt of Notice of Non-Compliance with NYSE Continued Listing Requirements On November 21, 2023, FOXO Technologies Inc. received an official notice of noncompliance from NYSE Regulation stating that the Company is not in compliance with NYSE American continued listing standards due to the failure to timely file the Company’s Form 10-Q for the period ended September 30, 2023 by the filing due date of November 20, 2023. “We regret the delay in filing our form 10-Q, which is due in large part to the substantive changes and necessary restructuring steps we have taken over the past several months,” stated Mark White, Interim CEO of Foxo Technologies. “Nevertheless, we have made substantial operational and financial progress. We are 100% committed to regaining compliance with the NYSE American’s continued listing requirements, and have taken steps to significantly enhance our financial infrastructure and ensure we meet the highest standards of corporate governance.” The Company is now subject to the procedures and requirements set in Section 1007 of the NYSE American Company Guide. Within five days of the date of the Filing Delinquency Notification, the Company was required to (a) contact the NYSE to discuss the status of the Delinquent Report and (b) issue a press release disclosing the occurrence of the Filing Delinquency, the reason for the Filing Delinquency and, if known, the anticipated date such Filing Delinquency will be cured via the filing or refiling of the applicable report, as the case may be. The NYSE American Notice has no immediate effect on the listing or trading of the Company’s Class A common stock on NYSE American. During the six-month period from the date of the Filing Delinquency, the NYSE will monitor the Company and the status of the Delinquent Report and any subsequent delayed filings, including through contact with the Company, until the Filing Delinquency is cured. If the Company fails to cure the Filing Delinquency within the Initial Cure Period, the NYSE may, in the NYSE’s sole discretion, allow the Company’s securities to be traded for up to an additional six-month period depending on the Company’s specific circumstances. If the NYSE determines that an Additional Cure Period is not appropriate, suspension and delisting procedures will commence in accordance with the procedures set out in Section 1010 of the NYSE American Company Guide. If the NYSE determines that an Additional Cure Period of up to six months is appropriate and the Company fails to file its Delinquent Report and any subsequent delayed filings by the end of that period, suspension and delisting procedures will generally commence. An issuer is not eligible to follow the procedures outlined in Section 1009 with respect to these criteria. Notwithstanding the foregoing, however, the NYSE may in its sole discretion decide (i) not to afford an issuer any Initial Cure Period or Additional Cure Period, as the case may be, at all or (ii) at any time during the Initial Cure Period or Additional Cure Period, to truncate the Initial Cure Period or Additional Cure Period, as the case may be, and immediately commence suspension and delisting procedures if the Company is subject to delisting pursuant to any other provision of the Company Guide, including if the NYSE believes, in the NYSE’s sole discretion, that continued listing and trading of an issuer’s securities on the NYSE is inadvisable or unwarranted in accordance with Sections 1001-1006 hereof. The Company intends to regain compliance with the NYSE American continued listing standards. There can be no assurance that the Company will ultimately regain compliance with all applicable NYSE American listing standards. Tillkännagivande • Nov 29
FOXO Technologies Inc. Announces the Resignation of Andrew Poole from the Board of Directors Effective November 21, 2023, FOXO Technologies Inc. accepted the resignation of Andrew Poole from the Board of Directors of the Company. Tillkännagivande • Nov 17
FOXO Technologies Inc. announced delayed 10-Q filing On 11/15/2023, FOXO Technologies Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Tillkännagivande • Nov 09
FOXO Technologies Inc. Plans to Unveil its New Direct-To-Consumer (DTC) App, the VITHAR™ AI Health Coach FOXO Technologies Inc. plans to unveil its new direct-to-consumer (DTC) app, the VITHAR™ AI Health Coach, which is designed to intake health data from available APIs already on the user's mobile and wearable devices, and combine this data with the individual's epigenetic data through the Company's proprietary epigenetic data and algorithms. The new DTC offering will leverage KR8's AI ecosystem to provide users with actionable health insights and coaching. Tillkännagivande • Oct 31
FOXO Technologies Inc. Unveils Plans for New Direct-To Consumer Offering Combining the Company's Epigenetic Data with the Power of Ai FOXO Technologies Inc. announced plans for a new subscription-based, direct-to-consumer product offering that will provide personalized health and wellness recommendations, by combining: (i) FOXO's machine learning models to analyze epigenetic biomarkers; (ii) the Company's expertise and algorithms correlating epigenetic analysis with health outcomes; and (iii) published, peer-reviewed, clinical data and other verified, third-party health resources. In connection with the new offering, the Company also announced it has formed a collaboration with KR8.ai Inc. ("KR8") and secured an exclusive license to KR8's AI-based software to support the development and commercial launch of the new health and wellness offering. Board Change • Oct 22
High number of new and inexperienced directors There are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. 2 experienced directors. No highly experienced directors. Independent Chairman of the Board & Member of Scientific Advisory Board Bret Barnes is the most experienced director on the board, commencing their role in 2021. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Tillkännagivande • Oct 14
FOXO Technologies Inc. Announces Issue Notification from USPTO for a Patent Leveraging Machine Learning Approaches to Enable the Commercialization of Epigenetic Biomarkers FOXO Technologies Inc. announced that the United States Patent & Trademark Office (USPTO) has provided an Issue Notification for a key patent utilizing a machine learning model trained to determine a biochemical state and/or medical condition using DNA epigenetic data to enable the commercialization of epigenetic biomarkers. Previously, the USPTO had issued Notices of Allowance to the Company for two related patents and the Company awaits Issue Notification for the second allowed patent. The first patent, for which the Company has received an Issue Notification, aids in practical applications of the technology that include generating epigenetic biomarkers. On occasion, epigenetic data may be missing or unreliable because a specific DNA site may not have been assayed or was unreliably measured. The patent allows the use of machine learning estimators to “fill in” the missing or unreliable epigenetic values at specific loci. The second patent, for which the Company received a Notice of Allowance, leverages machine learning to estimate aspects about an individual’s health, such as disease states, biomarker levels, drug use, health histories, and factors used to underwrite mortality risk. Commercial applications for this patent may include a potential AI platform for the delivery of health and well-being data-driven insights to individuals, healthcare professionals and third-party service providers, life insurance underwriting, clinical testing, and consumer health. To support these patents, the Company has generated epigenetic data for over 13,000 individuals through internally sponsored research and external research collaborations. Pairing these data with broad phenotypic information is expected to help drive product development as demonstrated in the Company’s patent claims. Tillkännagivande • Sep 13
FOXO Technologies Inc. announced that it has received $0.7435 million in funding On September 12, 2023, FOXO Technologies Inc. closed the transaction. The company has received gross proceeds of $743,500 in the transaction pursuant to Regulation D. The transaction included participation from 3 investors. Tillkännagivande • Sep 08
FOXO Technologies Inc. announced that it has received $0.2935 million in funding On September 7, 2023, FOXO Technologies Inc. closed the transaction. The company issued 1,834,375 shares of Common Stock at an issue price of $0.08 per share for the gross proceeds of $146,750 in second and final tranche. The Second Tranche Shares were issued and sold pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”) and Rule 506 of Regulation D promulgated thereunder. The Company has 55,644,642 shares of Common Stock issued and outstanding. Tillkännagivande • Sep 02
FOXO Technologies Announces NYSE American Acceptance of Compliance Plan On August 29, 2023, FOXO Technologies Inc. received a letter from NYSE American LLC stating that NYSE American reviewed and accepted the plan of compliance submitted by the Company in response to NYSE American’s June 12, 2023 notice informing the Company that it was not in compliance with the continued listing standards set forth in Section 1003(a)(i) of the NYSE American Company Guide. The Letter provides an extension for compliance with Section 1003(a)(i) of the Company Guide until December 12, 2024. NYSE American staff will review the Company periodically for compliance with the initiatives outlined in the Plan. If the Company is not in compliance with the continued listing standards by December 12, 2024, or if the Company does not make progress consistent with the Plan during the Plan period, NYSE American staff will initiate delisting proceedings as appropriate. As previously disclosed, the Company also received a second written notice on August 16, 2023, from NYSE American stating that it is not in compliance with the continued listing standard set forth in Section 1003(f)(v) of the Company Guide because the Company’s Class A common stock was selling for a substantial period of time at a low price per share, which NYSE American determined to be a 30-trading day average of less than $0.20 per share. The Second Notice stated that the Company’s continued listing is predicated on it effecting a reverse stock split of its Class A common stock or otherwise demonstrating sustained price improvement within a reasonable period of time, which NYSE American has determined to be no later than February 16, 2024. However, NYSE American may take an accelerated delisting action that would pre-empt the cure period in the event that the Class A common stock trades at a level viewed to be abnormally low. The Plan and the extension date referred to above do not apply to the February 16, 2024 deadline for the Company to comply with Section 1003(f)(v) of the Company Guide. The Company intends to effect a reverse stock split of its issued and outstanding shares of Class A common stock, which was previously approved by stockholders at the Company’s annual meeting of stockholders held on May 26, 2023, during the third quarter of 2023, but in any event, in advance of the February 16, 2024 deadline set forth in the Second Notice, to regain compliance with Section 1003(f)(v) of the Company Guide. The Company will continue to be included in the list of NYSE American noncompliant issuers, and the below compliance indicator will continue to be disseminated with the Company’s ticker symbol. The Company’s receipt of the Notices from NYSE American does not affect the Company’s business, operations or reporting requirements with the U.S. Securities and Exchange Commission. Tillkännagivande • Aug 24
FOXO Technologies Inc. announced that it expects to receive $0.2935 million in funding FOXO Technologies Inc. announced that it has entered into stock purchase agreement with three accredited investors to issue in two separate tranches each, an aggregate of up to 3,668,750 shares of the company’s Class A common stock, par value $0.0001 per share at a price of $0.08 per share for aggregate gross proceeds of $293,500 on August 23, 2023. The shares issued and to be issued pursuant to the stock purchase agreement were, and will be, sold pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended and Rule 506 of Regulation D promulgated thereunder.
On the same day, the company issued an aggregate of 1,834,375 shares of common stock in it first tranche and agreed to purchase an aggregate of 1,834,375 additional shares of common stock upon the effectiveness of the Resale Registration Statement. Tillkännagivande • Aug 21
FOXO Technologies Announces Receipt of Second Notice of Non-Compliance from NYSE American On August 16, 2023, FOXO Technologies Inc. received a second written notice (the ‘Notice’) from the NYSE American LLC (the ‘NYSE American’) stating that it is not in compliance with the continued listing standard set forth in Section 1003(f)(v) of the NYSE American Company Guide (the ‘Company Guide’) because the Company’s Class A common stock was selling for a low price per share for a substantial period of time, which NYSE American determined to be a 30-trading day average of less than $0.20 per share. The Notice stated that the Company’s continued listing is predicated on it effecting a reverse stock split of its Class A common stock or otherwise demonstrating sustained price improvement within a reasonable period of time, which NYSE American has determined to be no later than February 16, 2024. However, NYSE American may take accelerated delisting action that would pre-empt the cure period in the event that the Class A common stock trades at levels viewed to be abnormally low. As previously disclosed, on June 12, 2023, the Company received a notice from the NYSE American stating that it is not in compliance with the continued listing standards set forth in Section 1003(a)(i) of the Company Guide since the Company reported stockholders’ deficit of $(30,000) at March 31, 2023, and losses from continuing operations and/or net losses in its two most recent fiscal years ended December 31, 2022. Section 1003(a)(i) of the Company Guide requires a listed company to have stockholders’ equity of $2 million or more if the listed company has reported losses from continuing operations and/or net losses in two of its three most recent fiscal years. On July 12, 2023, the Company submitted a plan of compliance (the ‘Plan’) addressing how it intends to regain compliance with the stockholders’ equity requirement by December 12, 2024. If the Plan is not accepted by NYSE American, or if the Company does not make progress consistent with the Plan, or if the Company fails to regain compliance by December 12, 2024, the NYSE American may commence delisting procedures. The Company’s Class A common stock will continue to be listed on the NYSE American while the Company evaluates its various alternatives to regain compliance with Section 1003(f)(v) of the Company Guide, including to effect a reverse stock split of its issued and outstanding shares of Class A common stock, which corporate action was previously approved by stockholders at the Company’s annual meeting of stockholders held on May 26, 2023. The Company will also continue to be included in the list of NYSE American noncompliant issuers, and the below compliance (‘.BC’) indicator will continue to be disseminated with the Company’s ticker symbol. The Company’s receipt of the Notice from the NYSE American does not affect the Company’s business, operations or reporting requirements with the U.S. Securities and Exchange Commission. Tillkännagivande • Aug 09
FOXO Technologies Inc. to Report Q2, 2023 Results on Aug 10, 2023 FOXO Technologies Inc. announced that they will report Q2, 2023 results After-Market on Aug 10, 2023 Tillkännagivande • Jul 23
FOXO Technologies Inc. Reduces Employee Headcount via Layoffs On July 21, 2023, FOXO Technologies Inc. reduced its employee headcount via layoffs from 22 employees to 15 employees. Laid off employees will be paid through July 21, 2023 and will be eligible for unemployment benefits subject to local regulations. These layoffs will allow the Company to reduce its operating expenses while tailoring its strategic focus towards initiatives such as the Company’s recently announced Bioinformatics Services which offers epigenetic data processing and analysis. Tillkännagivande • Jul 22
FOXO Technologies Inc. Launches Bioinformatics Services to Revolutionize Epigenetic Data Analysis FOXO Technologies Inc. announced the launch of its Bioinformatics Services to accelerate breakthroughs in biology, biotechnology, and healthcare, and redefine the growing field of epigenetic research. FOXO’s Bioinformatics Services offers a comprehensive platform of advanced data solutions tailored to meet the specific needs of clients in academia, healthcare, and pharmaceutical research. Through its innovative suite of bioinformatic tools, FOXO will enable its clients to increase the speed and accuracy with which they process, analyze, and interpret data sets, accelerate discoveries, and advance their understanding of complex diseases. Any researcher or research group that seeks to leverage DNA methylation microarrays can benefit from FOXO’s Bioinformatics Services. These services include ingesting and processing raw DNA methylation microarray data, performing sample- and probe-level quality control, and securely delivering publication-ready figures and results. FOXO’s expert team also offers the addition of advanced bioinformatic analyses including epigenome wide association studies (EWAS), and even AI-driven epigenetic biomarker development. These services can be applied to Illumina’s existing human and mouse DNA Methylation arrays, which cover over 935,000 and 285,000 CpG sites respectively. By leveraging algorithms and world-class experts, the company’s bioinformatics platform can rapidly deliver accurate and high-quality data tailored to the needs of each client. As a leader in the field, FOXO remains committed to advancing epigenetic research and catalyzing breakthroughs in health and longevity. With Bioinformatic Services, FOXO is also opening the door to new research collaborations with industry and academic leaders. New Risk • Jul 09
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: US$9.53m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (24% average weekly change). Negative equity (-US$30k). Shareholders have been substantially diluted in the past year (80% increase in shares outstanding). Revenue is less than US$1m (US$484k revenue). Market cap is less than US$10m (US$9.53m market cap). Tillkännagivande • Jun 17
FOXO Technologies Announces Receipt of Notice of Non-Compliance with NYSE Continued Listing Requirements On June 12, 2023,FOXO Technologies Inc. received an official notice of noncompliance (the “NYSE American Notice”) from NYSE Regulation (“NYSE”) stating that the Company is below compliance with Section 1003(a)(i) in the NYSE American Company Guide (the “Company Guide”) since it reported stockholders’ deficit of $(30,000) at March 31, 2023, and losses from continuing operations and/or net losses in its two most recent fiscal years ended December 31, 2022. Section 1003(a)(i) of the Company Guide requires a listed company to have stockholders’ equity of $2 million or more if the listed company has reported losses from continuing operations and/or net losses in two of its three most recent fiscal years. The Company is now subject to the procedures and requirements set forth in Section 1009 of the Company Guide. The Company has until July 12, 2023, to submit a plan (the “Plan”) advising of actions it has taken or will take to regain compliance with the continued listing standards by December 12, 2024. If NYSE accepts the Plan, the Company will have an eighteen (18) month cure period to comply with the Plan and will be subject to periodic reviews including quarterly monitoring for compliance with the Plan. The NYSE American Notice has no immediate effect on the listing or trading of the Company’s Class A common stock on NYSE American, which will continue trading on the NYSE American under the symbol “FOXO”. The Company intends to consider available options to regain compliance with the stockholders’ equity requirement, but no decisions have been made at this time. There can be no assurance that the Company will ultimately regain compliance with all applicable NYSE American listing standards. Tillkännagivande • Jun 09
FOXO Technologies Inc. announced that it has received $3.806125 million in funding On June 8, 2023, FOXO Technologies Inc. closed the transaction. The transaction included participation from 106 investors. 
